Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma by O'BrienP et al.
Phase II Mult icenter Study of Brie f Single -Agent
Methotrexate Fol lowed by Irradiat ion in Primary
CNS Lymphoma
By P. O’Brien, D. Roos, G. Pratt, K. Liew, M. Barton, M. Poulsen, I. Olver, and G. Trotter
Purpose: To assess, in a multi-institutional setting,
the impact on relapse, survival, and toxicity of adding
two cycles of intravenous methotrexate to cranial irra-
diation for immunocompetent patients with primary
CNS lymphoma.
Patients and Methods: Forty-six patients with a me-
dian age of 58 years and Eastern Cooperative Oncol-
ogy Group performance status 0 to 3 were entered onto
this phase II study. The protocol consisted of methotrex-
ate 1 g/m2 on days 1 and 8 followed by cranial irradi-
ation on day 15. A whole-brain dose of 45 Gy was
followed by a boost of 5.4 Gy. Intrathecal chemother-
apy and spinal irradiation were given only to patients
for whom cytologic examination of CSF was positive for
CNS lymphoma. The median follow-up time was 36
months, with a minimum potential follow-up of 12
months.
Results: Median survival was 33 months, with
2-year probability of survival 62% 6 15% (95% confi-
dence interval). Twenty patients have relapsed. The
predominant site of relapse was the brain. Neither
performance status nor age was found to influence
survival. Six patients developed a dementing illness at
a median of 16 months after treatment, and three of
these died as a consequence.
Conclusion: A brief course of intravenous metho-
trexate before cranial irradiation is associated with
2-year and median survival rates superior to those
reported for radiotherapy alone and similar to more
intensive combined-modality regimens. Neurotoxicity
remains an important competing risk for these patients.
J Clin Oncol 18:519-526. © 2000 by American
Society of Clinical Oncology.
PRIMARY CNS LYMPHOMA (PCNSL) has attractedincreasing attention in the literature, first because of
the rapid increase in incidence as a consequence of the
human immunodeficiency virus epidemic and then because
of the recognition that the incidence was also increasing in
the immunocompetent population.1-4 Analysis of the Sur-
veillance, Epidemiology, and End Results database showed
an increased incidence that was independent of age and sex
from 2.5 to 30 cases per 10 million between 1973 and
1992.3 Its tropism for the CNS, which remains largely
unexplained, and low rates of systemic dissemination logi-
cally led to the use of radiotherapy alone as definitive
management.5-9 Despite doses of radiotherapy that would be
expected to control most non-Hodgkin’s lymphomas at
other sites, local failure was extremely common.10 This
propensity for local recurrence was best demonstrated in a
large phase II study performed by the Radiation Therapy
Oncology Group, in which doses of 50 to 60 Gy were
delivered to macroscopic disease.11 Sixty-one percent of
patients relapsed in the brain; this produced a median
survival of 11.6 months and a 2-year survival probability of
28%. This experience is reflected by all but two retrospec-
tive reviews of the results of radiotherapy alone. These two
single-institution studies report better median and overall
survival in modern patient cohorts.12,13
Awareness of the aggressive behavior of PCNSL and, in
particular, its resistance to local therapy alone has led to
investigations of alternative approaches to treatment. The
potential for chemotherapy to affect survival was first
suggested by reports of treatment after postirradiation re-
lapse.14 Since then several studies of combined-modality
therapy and chemotherapy alone have been performed.15-26
Two of the earliest combined-modality studies have pro-
duced the best results, with median cause-specific survival
of 42 months and 5-year probability of survival of 34%.15,16
Both of these studies come from single institutions and
could be broadly described as using methotrexate-based
chemotherapy. Whether the improvement in survival out-
come reflects the choice of chemotherapy regimen is un-
clear, but two multi-institutional prospective phase II stud-
ies have been unable to reproduce these results using
cyclophosphamide, doxorubicin, vincristine, and pred-
nisone (CHOP) or using cyclophosphamide, doxorubicin,
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vincristine, and dexamethasone before radiotherapy.17,18
The inability of CHOP regimens to improve survival sig-
nificantly has been attributed to poor blood-brain barrier
(BBB) penetration. This may be particularly true outside the
immediate region of tumor involvement, where theoreti-
cally BBB integrity is greater.27 One of the most widely
quoted series is that from the Memorial Sloan-Kettering
Cancer Center.15 Researchers there used preirradiation
methotrexate, with intrathecal therapy in all patients, fol-
lowed by radiotherapy and high-dose cytarabine (Ara-C) to
complete treatment. Although this produced impressive
survival in comparison with radiotherapy alone, there was a
cost in terms of neurotoxicity. Ten (32%) of 31 patients
developed a dementia-ataxia syndrome that required insti-
tutional care. This complication was significantly more
common in patients more than 60 years old.15
Our group sought to investigate the potential advantages
of adding a brief course of intravenous (IV) methotrexate to
cerebral irradiation, without routine use of CSF prophylaxis
or postirradiation Ara-C. We hypothesized that this protocol
would provide better survival than radiotherapy alone,
similar to the Memorial Sloan-Kettering series, and that it
would result in less treatment-related neurotoxicity. This
represents one of the first multi-institutional studies of a
methotrexate-only combined-modality regimen and ex-
pands on a preliminary report.28
PATIENTS AND METHODS
Eligibility and Assessment
Under the auspices of the Trans-Tasman Radiation Oncology Group,
46 patients were entered onto this phase II study from 12 centers in
Australia and New Zealand between 1991 and 1997. From 1994,
members of the Australasian Radiation Oncology Lymphoma Group
also contributed to the study. Patients were registered with the
Trans-Tasman Radiation Oncology Group central trials office, at which
time eligibility was confirmed. No further information was sought on
patients who were not registered because they were deemed ineligible
either at the time of attempted registration or by the participating
institutions. Considering the incidence of PCNSL and the populations
served by the participating institutions, it is unlikely that the study
group was selected according to factors other than the predefined
eligibility criteria.
Patients were considered eligible if histologic examination con-
firmed PCNSL, if serologic examination revealed no human immuno-
deficiency virus, and if their Eastern Cooperative Oncology Group
performance status (ECOG) was 0 to 3.29 Adequate baseline hemato-
logic, renal, and hepatic function was required with granulocyte counts
greater than 1,500 3 106, platelet counts greater than 100,000 3 106/L,
serum creatinine levels less than 0.15 mmol/L, and serum bilirubin and
AST levels less than two times the upper limit of normal. All patients
were required to give informed consent, and the protocol was approved
by the ethics committee of each institution.
Primary radiologic assessment was made using either computerized
tomography (CT) or magnetic resonance imaging (MRI) of the brain. A
CSF cytologic examination was required, but if raised intracranial
pressure prevented a lumbar puncture, it could be delayed until the
intracranial pressure had lessened. Only if the cytologic examination of
CSF revealed clear evidence of malignant lymphocytes was the CSF
considered to be involved. Immunohistochemical studies were not
required, although they are standard practice in most centers. More
sophisticated analysis, such as polymerase chain reaction for immuno-
globulin gene rearrangements, was not performed on CSF. Abnormal-
ities in protein and glucose levels were not considered diagnostic of
CSF involvement. Staging investigations to assess the potential pres-
ence of lymphoma outside the CNS included CT of the thorax,
abdomen, and pelvis, bone marrow trephine and biopsy, and ophthal-
mologic slit-lamp examination.
Protocol Treatment
Methotrexate 1 g/m2 was given as an IV infusion during a 6-hour
period on days 1 and 8. Leucovorin, 15 mg orally every 6 hours for 72
hours, was started 24 hours after the methotrexate infusion was begun.
If nausea or vomiting occurred during or after methotrexate, then
leucovorin was given intravenously until oral medication could be
tolerated. The patient was hydrated before and after infusion as part of
the protocol to maintain urinary pH at less than 7, using sodium
bicarbonate.
Intrathecal chemotherapy was given only to patients whose cytologic
CSF studies were positive. Sixty milligrams of Ara-C was given twice
weekly for 3 weeks starting on day 1 or as soon as possible after
diagnosis of CSF involvement. Weekly Ara-C continued for three
doses after clearance of the CSF.
The dose of dexamethasone was not specified because most patients
were referred for management after dexamethasone had been started by
the neurosurgical team. The protocol suggested that the dosage of
dexamethasone be kept to the minimum required to manage the patient
without producing deterioration in focal neurologic signs or symptoms
of raised intracranial pressure. It was suggested that low-dose dexa-
methasone be continued throughout radiotherapy and that every at-
tempt be made to withdraw corticosteroids at the completion of
treatment.
Radiotherapy started on day 15. All patients were treated using an
immobilization shell with customized shielding. Phase I of treatment
was delivered to a volume including the whole brain (specifically
denoted to include the optic nerve and cribriform plate) to the inferior
border of the foramen magnum or the inferior border of the body of C2
(depending on individual center preference). A dose of 45 Gy pre-
scribed to the midplane at the central axis of the treatment volume in 25
fractions was required to be delivered using opposed lateral fields; all
fields were treated daily and were given five fractions per week. There
was an option for reduction of the field from C2 to the inferior border
of the foramen magnum at 39.6 Gy in patients with reduced separation
and hence a high dose to the cervical spine at this level. Phase II of
radiotherapy delivered another 5.4 Gy to the isocenter in three fractions
of 1.8 Gy to a volume that depended on the number of sites of initial
involvement in the brain. If there were one or two sites, the phase II
volume included the prechemotherapy disease, defined as contrast-
enhancing tumor (but not edema) with a 1-cm margin as encompassed
by the 95% isodose contour. With two sites the boost could be
delivered as a single volume or as two separate volumes. If there were
more than two sites of disease, then the whole brain volume given in
phase I was taken to a total dose of 50.4 Gy. Spinal irradiation was only
given to patients with spinal cord involvement or whose cytologic
examination of CSF was positive. A total of 36 Gy was delivered to the
posterior aspect of the cord in 24 fractions for 5 weeks at 1.5
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Gy/fraction. The field extended from the lower border of the cranial
field at C2 to S3.
Follow-Up and Response Assessment
After patients completed all treatment, they were observed monthly
for 2 months, then every 4 months with a CT or MRI of the brain to be
performed 6 to 8 weeks after completion of radiotherapy. Additional
follow-up scans were performed yearly or more often if clinically
indicated.
Response was based on the following criteria: Complete response
referred to the absence of any tumor enhancement on the posttreatment
contrast CT scan. The patient was required to be off all dexamethasone.
Partial response referred to a reduction in at least 50% of the
contrast-enhancing CT volume, which is the sum of the products of all
the maximum diameters of the measured lesion or lesions. Stable
disease indicated objective regression of the measured contrast-enhanc-
ing CT volume, less than required to meet the criteria for partial
response or less than a 25% increase in the measurable lesion.
Progressive disease referred to an increase in the sum of the products
in the maximum diameters by 25% or more. Acute toxicity was graded
according to World Health Organization criteria.30
Statistics
The initial accrual target of this phase II study was 30 patients.
Historic data at that time indicated 2-year survival probability after
radiotherapy alone was 20% to 30%. However, it became apparent that
the 95% confidence intervals (CIs) for the survival calculation at 2
years would not be sufficiently narrow to support the hypothesis of a
significant improvement over historic controls treated with radiother-
apy alone. It was therefore decided to continue accrual until the 95%
CIs around the survival estimate at 2 years were 15% or less. It was also
decided that in view of potential neuropsychiatric sequelae from
treatment, at least 20 patients should have uncensored follow-up of 2
years or more. Survival and progression-free survival were estimated
using the product limit method of Kaplan-Meier and calculated from
the date of the start of chemotherapy. The log-rank test was used to
compare survival outcomes among subgroups. Survival was measured
until the date of death or last follow-up, and progression-free survival
was until the date of progression or last follow-up.
RESULTS
Patients
Forty-six patients were entered onto the study between
1991 and 1997. Table 1 lists the characteristics of the
patients. The median age was 58 years (range, 25 to 76
years), and 48% had an ECOG performance status of 0 or 1.
Diagnosis was made by open biopsy in 43.5%, stereotactic
biopsy in 43.5%, and excision biopsy in 13% of cases. Most
patients had diffuse large-cell subtype (working formula-
tion), although in 25% of cases it was impossible to
subcategorize the lymphoma. In one case the immunophe-
notype was T-cell. The median follow-up was 36 months,
and the minimum potential follow-up was 12 months. No
patient was lost to follow-up.
Protocol Compliance
In five cases, staging was incomplete because of CSF
cytology not being performed (four cases) and the omission
of slit-lamp examination (one case). Forty-five of the 46
patients received two doses of IV methotrexate as stipulated
in the protocol. In all but four cases these were delivered 7
days apart, with the others given on day 8. One patient did
not receive a second dose of methotrexate because of
progression of neurologic symptoms. One of the three
patients whose cytologic examination of CSF was positive
did not receive intrathecal Ara-C or spinal irradiation.
Forty-five of the 46 patients proceeded to radiotherapy
after chemotherapy. In one case fatal neutropenic sepsis
occurred after the second dose of methotrexate and before
the start of radiotherapy. Thirty-seven patients received 50.4
Gy, with four patients each receiving 54 Gy and 45 Gy. The
median duration of radiotherapy was 39 days (range, 36 to
51 days). For the 44 patients who received two doses of
methotrexate, radiotherapy was started no more than 10
days later in 41 (93%) and on days 11, 16, and 18 in the
remaining three.
Table 1. Patient and Tumor Characteristics
Characteristic
No. of Patients
(N 5 46) %
Age, years
Median 58
Range 25-76
Sex
Male 33
Female 13
ECOG Performance Status
0 4 9
1 18 39
2 18 39
3 6 13
No. sites in brain
Focal 27
Multifocal 19
Pathologic examination
Diffuse large cell 25 54
Not otherwise specified 12 26
Diffuse mixed 4 9
Diffuse small cleaved 3 7
Immunoblastic 2 4
CSF Cytologic examination
Positive 3 6
Negative 39 85
Unknown 4 9
Ocular involvement
Yes 2 4
No 43 94
Unknown 1 2
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Response and Survival
One patient who died after a septic episode subsequent to
chemotherapy and six patients who underwent complete
surgical excision of their tumors were not assessable for
response (as evaluated 6 weeks after completing all treat-
ment). Of the remaining 39 patients, 32 (82%) had a
complete response, five (13%) had a partial response, and
one each had stable and progressive disease. The median
survival for the entire group was 33 months, with a 2-year
probability of survival of 62% 6 15% (95% CI) (Fig 1).
Three patients were alive 48 months or more after treatment.
Two died at 79 and 83 months, respectively; in both cases
the cause of death was recurrent PCNSL. One of these
recurrences was in brain and the other was extranodal
(muscle). In total, 20 patients developed progressive disease
at a median time of 17 months after starting treatment
(range, 1 to 60 months). Fourteen patients progressed or
relapsed in the brain, which was the predominant site. The
other sites of progression were the spinal cord (two pa-
tients), eye (one patient), and CSF (two patients); systemic
disease developed in four patients (three of these disease
sites were extranodal—two in muscle and one in skin).
None of the patients who relapsed in the CSF or the spinal
cord was positive for CSF involvement at the time of
diagnosis. Of the three patients with positive CSF involve-
ment, one relapsed in brain in the high-dose radiotherapy
volume. Progression-free survival at 2 years was 65% 6
15% (95% CI) (Fig 2).
Five patients died from causes other than recurrent or
progressive PCNSL. Three of these had late neuropsychi-
atric sequelae. Another patient, who had an ECOG perfor-
mance status of 3 at the time of diagnosis but did not
improve functionally despite a radiologic complete re-
sponse, committed suicide 12 months after treatment. The
fifth patient, who also had an ECOG status of 3, had a
partial response to treatment but died from pneumonia 7
weeks later.
Neither performance status, age, nor presence of focal
versus multifocal disease was found to affect survival. The
2-year probability of survival for patients with an ECOG
status of 0 to 1 was 66% versus 58% for those with an
ECOG status of 2 to 3 (P 5 .47). Many groups have found
increasing age to be of prognostic significance. There was
no difference in survival for patients older than 60 years of
age. Probability of 2-year survival was 57% for patients
younger than 60 years versus 69% for those 60 years or
older (P 5 .94)
Patients responding to treatment and not progressing
within 6 months were evaluated for any change in perfor-
mance status. Forty-eight percent and 55% of patients had
improved performance status at 2 and 6 months after
treatment. Fourteen percent had deteriorated at 2 months
despite response of their disease.
Toxicity
Acute toxicity during treatment was generally minimal
(Table 2). However, one death was due to neutropenic
sepsis after the second dose of methotrexate. Most patients
developed alopecia, which was only partially reversible.
Six patients developed a dementing disease, consistent
with a late neurotoxic effect of treatment. In all six cases,
repeat MRI or CT failed to show recurrent PCNSL, and in
most cases revealed the characteristic features of late
radiation injury, with cortical thinning, ventricular enlarge-
ment, and white matter changes. The age of the patients at
the time of treatment ranged from 52 to 73 years (median,
61 years), with a time to onset of 12 to 30 months (median,
16 months). Four of these six patients have required
Fig 2. Progression-free survival.
Fig 1. Overall survival.
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institutional care and three have died. Another patient was
thought to have developed late neuropsychiatric sequelae
with typical MRI appearances but at autopsy was found to
have diffuse infiltration of the brain with PCNSL. The
Kaplan-Meier estimate of probability of neurotoxicity was
22% at 30 months (Fig 3).
DISCUSSION
Progress in the treatment of PCNSL has been slower than
that in nodal and other selected extranodal lymphomas
because of its rarity, which makes large-scale randomized
studies difficult. Improvements in survival outcome using a
combined-modality approach have been pioneered mostly
in single-institution studies.15,16,19,20 These studies have all
used methotrexate alone or in combination with other
chemotherapeutic agents followed by radiotherapy. Thus
far, two multi-institutional studies could not reproduce the
improvements in survival using combined-modality regi-
mens, but this may relate to the selection of chemotherapy
using CHOP or cyclophosphamide, doxorubicin, vincris-
tine, and dexamethasone.17,18 Our study allows some as-
sessment of the potential gains from adding a simple
regimen of two cycles of IV methotrexate to cerebral
irradiation in a multi-institutional setting. The median sur-
vival of 33 months was superior to all prospective studies of
radiotherapy alone. Selection criteria are unlikely to explain
these results, as 52% of patients had an ECOG status of 2 or
3 and the median age was 58 years. The 2-year probability
of survival was 62%, and three patients were alive and
disease-free 4 or more years after treatment. Interestingly,
two patients relapsed 5 years after treatment, one in the
brain and the other in an extranodal site. The Memorial
Sloan-Kettering series reports relapse as late as 51 months
after combined-modality therapy.15 Longer follow-up will
allow a more accurate estimate of the risk of late relapse.
Unlike other combined-modality studies, older patients
did not have poorer survival prospects than their younger
counterparts.15,17-20 Of the patients 60 years of age or older,
45% had an ECOG status of 0 or 1, and 40% had focal
disease. This is not different from the group as a whole and
does not suggest an influence of selection factors. The
number of patients is small; therefore multivariate modeling
may be unreliable. Even so, analysis using the Cox propor-
tional hazards model does not suggest age, performance
status, or focality to be of prognostic significance (data not
shown). It may be that the efficacy of the regimen combined
with its simplicity and lack of acute toxicity allows patients
to complete treatment and hence is associated with a better
chance of long-term survival. The ability to get most
patients through the acute effects of any protocol is impor-
tant in extrapolating its use to patients outside the controlled
environment of a phase II study. This is particularly true in
PCNSL, where up to 50% of patients are more than 60 years
of age and often have worse performance status than
patients with systemic non-Hodgkin’s lymphoma.
Age may be important not only in terms of acute
tolerance but also in potential risk of late neurotoxicity.
Thus far, six patients have developed late neurotoxicity,
which presented as a dementing process. Once established,
this process has been progressive and irreversible; most of
these patients have required institutional care. Neither
baseline nor prospective neuropsychiatric evaluation was a
requirement of the protocol, so the number of cases identi-
fied may represent a minimal estimate. Kaplan-Meier esti-
mates are often used to quantify the risk of neuropsychiatric
sequelae, but this method may overestimate the real risk in
such small studies.31 Nevertheless, this debilitating conse-
quence of treatment is distressing to patients and their
families.
Different approaches are being taken in an effort to
minimize late neurotoxicity, including the omission of
radiotherapy. The use of chemotherapy alone in PCNSL has
involved variations in the agents and dose-intensity, up to
and including the use of autologous bone marrow transplan-
tation.21-24,32,33 An impressive median survival of 44Fig 3. Kaplan-Meier plot of neurotoxicity.
Table 2. Acute Toxicity
Grade (no. of patients)
0 1 2 3 4
Neutropenia 35 4 3 1 3
Thrombocytopenia 42 1 1 1 1
Stomatitis* 29 7 8 1 0
Nausea and vomiting* 21 11 8 5 0
* Data are missing for one patient who had fatal neutropenic sepsis.
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months has been obtained using BBB disruption with
combination chemotherapy based around methotrexate.21
Again, this was a single-institution study and the intensive
nature of the regimen limits its widespread applicability.
Preliminary results are promising in a relatively small
number of cases using other methotrexate-based regi-
mens.23,24 The longer-term results of these and other ongo-
ing studies are awaited with interest, in terms not only of
efficacy but also of long-term toxicity. Acute toxicity needs
to be considered in debilitated patients. Treatment-related
deaths while using chemotherapy alone have been as high as
10%.32 Neurotoxic effects are not limited to studies using
radiation. In one prospective study of chemotherapy alone,
with a median follow-up of 3.3 years, three of 14 patients
developed severe leukoencephalopathy.33 As a proportion,
this is similar to our combined-modality series. The other
approach being taken is to intensify chemotherapy and
decrease the dose of irradiation, often excluding elderly
patients, in an effort to avoid neurotoxicity. Eventually, a
randomized study will be required to establish a gold
standard for efficacy and toxicity. In all likelihood this will
need to be an international effort. The incidence of PCNSL
in the immunocompetent population has risen during the
last 20 years, but this disease remains relatively uncommon,
and it took 7 years to accrue 46 cases in this study of
patients from Australia and New Zealand.3
The combination of methotrexate and irradiation is
clearly implicated in the development of late neurotoxicity,
but the disease process itself may also play a part. Primary
CNS lymphoma has a predisposition for perivascular infil-
tration, which may contribute to the marked breakdown in
the BBB. The importance of BBB integrity has been
stressed in the study of late radiation injury of the CNS.34
Although the late morphologic effects of irradiation on the
brain are well documented, debate continues about the
relative contributions of vascular and direct neural injury,
particularly when leukoencephalopathy rather than necrosis
is the end point of interest.35 Some evidence suggests that
the pathogenesis of intellectual impairment relates to vas-
cular injury in the hippocampal region.36 The cause-and-
effect issue remains unresolved by animal models, with
changes seen in microvasculature, neuropil, neuronal bod-
ies, and astrocytes.37 Radiation effects on vascular tissue,
particularly endothelial cells and smooth muscle cells, may
be mediated in part by a procoagulant environment.38,39 It
remains to be seen whether developments in the therapy of
vascular disorders with morphologic effects similar to those
of radiation hold any promise in reducing this serious
treatment effect.40
Because it is believed that the leptomeninges and CSF are
predominant sites of relapse, it has been common to
recommend that all patients receive intrathecal chemother-
apy.41 There is a legitimate concern that the interaction
between intrathecal methotrexate and cranial irradiation
increases the risk of late cerebral injury.42 The BBB is
disrupted in the presence of PCNSL and it is likely that
cytotoxic levels of methotrexate will occur in the CSF after
doses as low as 1 g/m2 are given intravenously.43,44 Only
two patients in our series suffered CSF relapse, so intrathe-
cal therapy can probably be avoided in most patients,
reserving it for those with CSF involvement at the time of
diagnosis, provided adequate doses of IV methotrexate are
used. Similarly, it is unlikely that spinal irradiation has a
role other than in the rare patient with spinal cord involve-
ment at the time of diagnosis.
Our group is still wrestling with an appropriate follow-up
to this phase II study. Two recent randomized studies in
localized intermediate-grade non-Hodgkin’s lymphoma
provide persuasive evidence of an advantage for combined-
modality therapy over chemotherapy alone.45,46 One of the
attractive aspects of our regimen was its ease of deliverabil-
ity in elderly patients, who are often debilitated by the
disease. Major questions still exist as to the best drugs,
doses, and timing for combined-modality regimens, and
whether radiotherapy doses can be kept below 40 Gy. Our
strategy is to maximize the potential efficacy of chemother-
apy given before BBB repair and reduce the dose of
radiotherapy. Although anthracyclines have some penetra-
tion in the presence of BBB disruption, this is likely to be
limited, as evidenced by studies using CHOP. Liposomal
daunorubicin may provide a method of using an anthracy-
cline with activity in non-Hodgkin’s lymphoma and im-
proved tumor uptake and endothelial penetration in the
setting of BBB disruption.47,48 Pharmacokinetic studies in
patients with astrocytomas treated with liposomal daunoru-
bicin indicate prolonged intratumor levels of the active
metabolite daunorubicinol.49 Methotrexate remains the
most important single agent because of its BBB penetration
and activity. By increasing the total dose of methotrexate
and combining it with an active anthracycline before radio-
therapy, we hope to produce a therapeutic advantage.
This multi-institutional study has shown that in a phase II
setting, methotrexate given immediately before irradiation
seems to improve median survival outcome for patients with
PCNSL. Neuropsychiatric sequelae remain an important
competing risk for these patients. The challenge is to
maintain or improve survival while minimizing this risk.
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APPENDIX
Contributors to This Study
In Australia: P. O’Brien, MD, Department of Radiation Oncology, Newcastle Mater Hospital, Newcastle, New South Wales; D. Roos, MD, Royal
Adelaide Hospital Cancer Centre, Adelaide, South Australia; G. Pratt, MD, Queensland Radium Institute, Royal Brisbane Hospital, Brisbane,
Queensland; K. Liew, MD, Peter MacCallum Cancer Institute, Melbourne, Victoria; M. Barton, MD, Department of Radiation Oncology, Westmead
Hospital, Westmead, New South Wales; M. Poulsen, MD, Queensland Radium Institute, Mater Hospital, Brisbane, Queensland; I. Olver, MD, Royal
Adelaide Hospital Cancer Centre, Adelaide, South Australia; G. Delaney, MD, Department of Radiation Oncology, Liverpool Hospital, Liverpool,
New South Wales; C. Macleod, MD, Radiation Oncology Department, Royal Prince Alfred Hospital, Camperdown, New South Wales; S. Cooper,
MD, Radiation Oncology Department, St Vincent’s Hospital, Randwick, New South Wales; D. Christie, MD, East Coast Cancer Centre, Tugun,
Queensland; M. Holocek, MD, Radiation Oncology Department, Royal North Shore Hospital, Crows Nest, New South Wales; and D. Joseph, MD,
Charles Gairdner Hospital, Perth, Western Australia.
In New Zealand: G. Trotter, MD, Department of Radiation Oncology, Waikato Hospital, Hamilton; and C. Johnson, MD, Department of Radiation
Oncology, Wellington Hospital, Wellington.
Data management: Sue Wright.
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